Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand–1 Expression for Immunotherapy in Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand–1 Expression for Immunotherapy in Non–Small Cell Lung Cancer

Published:2018-04 Issue:1 Volume:287 Page:326-332
ISSN:0033-8419
Container-title:Radiology
language:en
Short-container-title:Radiology

Author:

Tsai Emily B.¹,Pomykala Kelsey¹,Ruchalski Kathleen¹,Genshaft Scott¹,Abtin Fereidoun¹,Gutierrez Antonio¹,Kim Hyun J.¹,Li Alice¹,Adame Carlos¹,Jalalian Ashkan¹,Wolf Brian¹,Garon Edward B.¹,Goldman Jonathan W.¹,Suh Robert¹

Affiliation:

1. From the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.

Publisher

Radiological Society of North America (RSNA)

Subject

Radiology, Nuclear Medicine and imaging

Link

http://pubs.rsna.org/doi/pdf/10.1148/radiol.2017170347

Reference25 articles.

1. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

2. Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

3. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

4. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease

5. Non–Small Cell Lung Cancer, PD-L1, and the Pathologist

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to D.-C. Mo et al;Journal of Clinical Oncology;2024-07-20

2. Repeat biopsy versus initial biopsy in terms of complication risk factors and clinical outcomes for patients with non-small cell lung cancer: a comparative study of 113 CT-guided needle biopsy of lung lesions;Frontiers in Oncology;2024-05-13

3. Metal Nanoparticles as Novel Agents for Lung Cancer Diagnosis and Therapy;Small;2023-02-02

4. Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer;Cancers;2022-04-02

5. Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective;Journal of Molecular Pathology;2021-08-18